# Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

> **NCT02145143** · EARLY_PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Thyroid Carcinoma

## Interventions

- **DRUG:** Vemurafenib
- **DEVICE:** serial 124I PET/CT
- **DRUG:** thyrotropin alpha

## Key facts

- **NCT ID:** NCT02145143
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-20
- **Primary completion:** 2024-11-21
- **Final completion:** 2024-11-21
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145143, "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02145143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*